French wrestle with major concerns over biosimilar substitution
This article was originally published in SRA
Executive Summary
French industry and government representatives are working to find ways to temper the effects of last December's law permitting biosimilar substitution, although their room for manoeuvre may be limited as the authorities will not want to backtrack and thereby lose face over this potentially cost-saving measure.